Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.P. Carrieri, C. Pradier, P. Piselli, M. Piche, E. Rosenthal, P. Heudier, et al.
Reduced incidence of Kaposi’s sarcoma and of systemic non-Hodgkin’s lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy.
Int J Cancer, 103 (2003), pp. 142-144
[2.]
U. Tirelli, M. Spina, G. Gaidano, E. Vaccher, S. Franceschi, A. Carbone.
Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy.
AIDS, 14 (2000), pp. 1675-1688
[3.]
L. Gerard, L. Galicier, A. Maillard, E. Boulanger, L. Quint, S. Matheron, et al.
Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival.
J Acquir Immune Defic Syndr, 30 (2002), pp. 478-484
[4.]
M. Corti, F. Villafañe, N. Trione, R. Schtirbu, C. Yampolsky, M. Narbaitz.
Linfomas primarios del sistema nervioso central en pacientes con sida.
Enf Infecc Microbiol Clin, 22(6 (2004), pp. 332-336
[5.]
M. Spina, A. Carbone, E. Vaccher, A. Gloghini, R. Talamini, R. Cinelli, et al.
Outcome in patients with non-Hodgkin lymphoma and with or without human immunodeficiency virus infection.
Clin Infect Dis, 38 (2003), pp. 142-144
[6.]
A. Antinori, A. Cingolani, L. Alba, A. Ammassari, D. Serraino, B.C. Ciancio, et al.
Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.
AIDS, 15 (2001), pp. 1483-1491
[7.]
E. Vaccher, M. Spina, R. Talamini, M. Zanetti, G. Di Gennaro, G. Nasti, et al.
Improvement of systemic human immunodeficiency virus-related non-Hodgkin’s lymphoma outcome in the era of highly active antiretroviral therapy.
Clin Infect Dis, 37 (2003), pp. 1556-1564
[8.]
J.T. Navarro, J.M. Ribera, A. Oriol, M. Vaquero, J. Romeu, M. Batlle, et al.
Influence of highly active antiretroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin’s lymphomas treated with cyclophosphamide, hydroydoxorubicin, vincristine and prednisone.
Br J Haematol, 112 (2001), pp. 909-915
[9.]
J.T. Navarro, J.M. Ribera, N. Lloveras, A. Oriol, J.L. Mate, M. Batlle, et al.
HIV-infected patients with diffuse large B-cell lymphoma treated with CHOP and HAART have similar outcome than HIV-negative patients receiving CHOP. Abstract 2370.
Blood, 102 (2003), pp. 642a
[10.]
J.T. Navarro, J.M. Ribera, A. Oriol, C. Tural, F. Millá, E. Feliu.
Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy.
J Acquir Immune Defic Syndr, 32 (2003), pp. 347-348
[11.]
C. Hoffmann, E. Wolf, G. Fätkenheuer, T. Buhk, A. Stoehr, A. Plettenberg, et al.
Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma.
AIDS, 17 (2003), pp. 1521-1529
[12.]
P. Miralles, C. Rubio, J. Berenguer, J.M. Ribera, F. Calvo, J. Díaz-Mediavilla, et al.
Recomendaciones de GESIDA/PETHEMA sobre diagnóstico y tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana.
Med Clin (Barc, 118 (2002), pp. 225-236
[13.]
R.F. Little, S. Pittaluga, N. Grant, S.M. Steinberg, M.F. Kavlick, H. Mitsuya, et al.
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumour biology.
Blood, 101 (2003), pp. 4653-4659
[14.]
A. Oriol, J.M. Ribera, J. Esteve, M.A. Sanz, S. Brunet, R. García Boyero, et al.
Intensive chemotherapy for Burkitt’s lymphoma and leukemia: similar results for HIV positive and negative adult patients treated with PETHEMA ALL3/97 protocol.
Haematologica, 88 (2003), pp. 445-453
[15.]
M. Spina, J.A. Sparano, U. Jaeger, G. Rossi, U. Tirelli.
Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin’s lymphoma and HIV infection.
AIDS, 17 (2003), pp. 137-138
[16.]
A. Re, C. Cattaneo, M. Michieli, S. Casari, M. Spina, M. Rupolo, et al.
High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy.
J Clin Oncol, 21 (2003), pp. 4423-4427
[17.]
J.M. Ribera, J.T. Navarro, A. Oriol, A. López-Guillermo, A. Sureda, E. Abella, et al.
Impact of highly active antiretroviral therapy on response to treatment and survival in patients with human immunodeficiency virus related Hodgkin’s disease.
AIDS, 14 (2002), pp. 1973-1977
[18.]
M. Spina, J. Gabarre, G. Rossi, M. Fasan, C. Schiantarelli, E. Nigra, et al.
Stanford V regimen and concomitant HAART in 59 patients with Hodgkin’s disease and HIV infection.
Blood, 100 (2002), pp. 1984-1988
[19.]
J.M. Ribera, J.T. Navarro, A. Oriol, J. Romeu, G. Sirera, C. Tural, et al.
Tratamiento de los linfomas en pacientes con infección por el virus de la inmunodeficiencia humana.
Haematologica, 88(Supl 6 (2003), pp. 63-71
[20.]
C. Hoffmann, S. Tabrizian, E. Wolf, C. Eggers, Stoehr, A. Aplettenberg, et al.
Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery.
AIDS, 15 (2001), pp. 2119-2127
[21.]
D.J. Skiest, C. Crosby.
Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma.
AIDS, 17 (2003), pp. 1787-1793
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
